Novo Nordisk A/S, of Bagsvaerd, Denmark, said it completed the phase II trial for OG217SC, its oral formulation of long-acting GLP-1 analogue semaglutide. The study investigated dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in approximately 600 people with type 2 diabetes.